Search

To evaluate the incidence of brachial plexus injury (BPI) following single-fraction stereotactic body radiation therapy (SBRT) to apical lung tumors.A retrospective cohort analysis was performed of all patients treated with single-fraction lung SBRT at our institution from 2007 to 2022. Apical tumors were identified as those with an epicenter located above the arch of the aorta. Dosimetric analysis of dose to the brachial plexus (BP) was done using both the subclavian vessel (SCV) surrogate structure and anatomic BP. BPI was assessed per CTCAE v4.0 as regional paresthesia, marked discomfort and muscle weakness, and limited movement of the arm or hand.A total of 45 patients met inclusion criteria with median follow up of 21 months. There were 9 patients that exceeded the BP dose constraint using the SCV or anatomic BP volume. Only 1 patient (2.2%) developed grade 2 BPI, occurring 7 months after SBRT. Dose to the anatomic BP for the affected patient was 26.39 Gy. For the entire cohort, the median SCV and anatomic maximum BP doses were 8.44 and 7.14 Gy, respectively.There is considerable variability in dose delivered to the BP after SBRT to apical lung tumors. BPI following single-fraction SBRT to apical tumors is rare and rates are comparable to those reported with multi-fraction regimens.

Purpose The aim of this study was to examine current practice patterns in pediatric total body irradiation (TBI) techniques among COG member institutions. Methods and Materials Between November 2019 and February 2020, a questionnaire containing 52 questions related to the technical aspects of TBI was sent to medical physicists at 152 COG institutions. The questions were designed to obtain technical information on commonly used TBI treatment techniques. Another set of 9 questions related to the clinical management of patients undergoing TBI was sent to 152 COG member radiation oncologists at the same institutions. Results Twelve institutions were excluded because TBI was not performed in their institutions. A total of 88 physicists from 88 institutions (63% response rate) and 96 radiation oncologists from 96 institutions (69% response rate) responded. The anterior-posterior/posterior-anterior (AP/PA) technique was the most common technique reported (49 institutions [56%]); 44 institutions (50%) used the lateral technique, and 14 (16%) used volumetric modulated arc therapy or tomotherapy. Midplane dose rates of 6 to 15 cGy/min were most commonly used. The most common specification for lung dose was the midlung dose for both AP/PA techniques (71%) and lateral techniques (63%). Almost all physician responders agreed with the need to refine current TBI techniques, and 79% supported the investigation of new TBI techniques to further lower the lung dose. Conclusions There was no consistency in the practice patterns, methods for dose measurement, and reporting of TBI doses among COG institutions. The lack of standardization precludes meaningful correlation between TBI doses and clinical outcomes including disease control and normal tissue toxicity. The COG radiation oncology discipline is currently undertaking several steps to standardize the practice and dose reporting of pediatric TBI using detailed questionnaires and phantom-based credentialing for all COG centers.

Background Radiation dose to specific cardiac substructures can have a significant on treatment related morbidity and mortality, yet definition of these structures is labor intensive and not standard. Autosegmentation software may potentially address these issues, however it is unclear whether this approach can be broadly applied across different treatment planning conditions. We investigated the feasibility of autosegmentation of the cardiac substructures in four-dimensional (4D) computed tomography (CT), respiratory-gated, non-contrasted imaging. Aim To determine whether autosegmentation can be successfully employed on 4DCT respiratory-gated, non-contrasted imaging. Methods We included patients who underwent stereotactic body radiation therapy for inoperable, early-stage non-small cell lung cancer from 2007 to 2019. All patients were simulated via 4DCT imaging with respiratory gating without intravenous contrast. Generated structure quality was evaluated by degree of required manual edits and volume discrepancy between the autocontoured structures and its edited sister structure. Results Initial 17-structure cardiac atlas was generated with 20 patients followed by three successive iterations of 10 patients using MIM software. The great vessels and heart chambers were reliably autosegmented with most edits considered minor. In contrast, coronary arteries either failed to be autosegmented or the generated structures required major alterations necessitating deletion and manual definition. Similarly, the generated mitral and tricuspid valves were poor whereas the aortic and pulmonary valves required at least minor and moderate changes respectively. For the majority of subsites, the additional samples did not appear to substantially impact the quality of generated structures. Volumetric analysis between autosegmented and its manually edited sister structure yielded comparable findings to the physician-based assessment of structure quality. Conclusion The use of MIM software with 30-sample subject library was found to be useful in delineating many of the heart substructures with acceptable clinical accuracy on respiratory-gated 4DCT imaging. Small volume structures, such as the coronary arteries were poorly autosegmented and require manual definition.

Simple Summary The optimal way to treat central (CLT) and ultracentral (UCLT) lung tumors with curative radiation is unclear. We evaluated 83 patients with CLT and UCLT who underwent a curative radiotherapy technique called stereotactic body radiation therapy (SBRT). On statistical analysis, patients with UCLT had worse overall survival. Using a cohort of patients matched for relevant variables such as gender and performance status, we evaluated radiation doses to critical central structures such as the airway and heart. In this group, patients with UCLT were more likely to exceed dose constraints as compared CLT, particularly constraints regarding the airway. Additionally, patients had worse non-cancer associated survival when radiation doses were higher than 18 Gy to 4cc’s of either the trachea or proximal bronchial tree. Based on these findings, patients with UCLT have worse outcomes which could be secondary to higher radiation doses to the trachea and proximal bronchial tree. Abstract The preferred radiotherapeutic approach for central (CLT) and ultracentral (UCLT) lung tumors is unclear. We assessed the toxicity and outcomes of patients with CLT and UCLT who underwent definitive five-fraction stereotactic body radiation therapy (SBRT). We reviewed the charts of patients with either CLT or UCLT managed with SBRT from June 2010–April 2019. CLT were defined as gross tumor volume (GTV) within 2 cm of either the proximal bronchial tree, trachea, mediastinum, aorta, or spinal cord. UCLT were defined as GTV abutting any of these structures. Propensity score matching was performed for gender, performance status, and history of prior lung cancer. Within this cohort of 83 patients, 43 (51.8%) patients had UCLT. The median patient age was 73.1 years with a median follow up of 29.9 months. The two most common dose fractionation schemes were 5000 cGy (44.6%) and 5500 cGy (42.2%) in five fractions. Multivariate analysis revealed UCLT to be associated with worse overall survival (OS) (HR = 1.9, p = 0.02) but not time to progression (TTP). Using propensity score match pairing, UCLT correlated with reduced non-cancer associated survival (p = 0.049) and OS (p = 0.03), but not TTP. Within the matched cohort, dosimetric study found exceeding a D4cc of 18 Gy to either the proximal bronchus (HR = 3.9, p = 0.007) or trachea (HR = 4.0, p = 0.02) was correlated with worse non-cancer associated survival. In patients undergoing five fraction SBRT, UCLT location was associated with worse non-cancer associated survival and OS, which could be secondary to excessive D4cc dose to the proximal airways.

PURPOSE/OBJECTIVE(S) Central (CLT) and ultracentral (UCLT) lung tumors can be at higher risk for treatment related mortality following stereotactic body radiation therapy (SBRT) and the preferred dose and fractionation is unclear. We assessed the toxicity and outcomes of patients with CLT and UCLT who underwent definitive five-fraction SBRT. MATERIALS/METHODS We reviewed the charts of patients with either CLT or UCLT managed with SBRT from June 2010-April 2019. CLT were defined as gross tumor volume within 2 cm of either the proximal bronchial tree, trachea, mediastinum, aorta, or spinal cord. UCLT were defined as GTV abutting any of these structures. Toxicity was graded by the Common Terminology Criteria for Adverse Events version 5.0. Propensity score matching was performed for gender, performance status, and history of prior lung cancer. Survival outcomes evaluated by Cox regression and Kaplan-Meier estimation. RESULTS Within this cohort of 83 patients, the median age was 73.1 years with a median follow up of 29.9 months. All patients underwent 5 fraction SBRT, with dose range of 50-60 Gy. Most patients had T1 tumors (68.7%) and 43 (51.8%) were considered UCLT. In 20 (50%) patients with CLT, the proximal bronchial tree was the closest central structure while the aorta was the closest structure in 16 (37.2%) of UCLT patients. Grade 2+ toxicity was similar between the two groups, 11 (27.5%) for CLT and 13 (30.2%) (P = 0.78) for UCLT patients. Furthermore, there was no difference in grade 3 toxicity with 3 (7.5%) CLT and 4 (9.3%) UCLT patients (P = 0.77) and no observed grade 4+ events. There was no difference in crude local failure (5% vs 7.0%) (P = 0.34) or recurrence rates (22.5% vs 9.3) (P = 0.09). Multivariate analysis adjusting for gender, performance status, prior lung cancer, history of diabetes, history of heart disease, and prescription volume revealed UCLT to be associated with worse overall survival (OS) (P = 0.02) but not freedom from progression (FFP). Using propensity score match pairing, 29 match pairs were generated finding UCLT to correlate with reduced non-cancer related survival (NC-OS) and OS, but not FFP. CONCLUSION Definitive 5 fraction SBRT yielded similar toxicity profiles for CLT and UCLT. Despite no difference in FFP, UCLT were associated with worse (NC-OS) and OS.

The study was designed to evaluate the cumulative dose exposure of brain and hippocampus following multiple stereotactic radiosurgery (SRS) procedures on a single patient. Ninety-four patients who received at least two SRS treatments were evaluated. Their SRS dose plans were summated to obtain dose volume parameters. Hippocampal structures were delineated, in addition to segmentation of the brain. A total of 267 treatments were delivered to 94 patients. The number of SRS procedures per patient varied from 2 to 7 (mean = 2.8), and the total number of lesions treated in a given patient over multiple treatments varied from 2 to 70 (mean = 11). The interval between the first and last SRS treatments varied from 1 to 79 months (mean = 16.2 months). The mean prescription dose was 16.7 Gy prescribed to isodose lines from 40 to 95%. The mean coverage, selectivity, Paddick conformity, and gradient index were 99.6%, 79%, 0.57, and 2.74, respectively. The mean summated dose delivered to the whole brain over the course of multiple treatments was 5.11 Gy. The hippocampal mean dose after summation was 2.95 Gy. Patients with plan PCIs averaging below the mean value of 0.57 had higher V8, V10, V12, and V15 values for a given total tumor volume when compared with more conformal plans (PCI > 0.57). Repeat SRS delivered low cumulative doses to the brain and hippocampus with the lowest normal brain volumes irradiated in highly conformal plans.

Determination of intrafraction motion in stereotactic body radiation therapy (SBRT) of non-small-cell lung cancer (NSCLC) usually involves generating an internal target volume (ITV) based on target segmentation in every one of the 10 phases of a 4-dimensional computed tomography (4DCT) dataset which increases dosimetry work load substantially. This study explores the feasibility of using a smaller number of phases to compile an ITV to get equivalent results. Twenty-five lung cancer patients treated with SBRT were retrospectively assessed. Patients were categorized by the anatomic location of the GTV within different lobes of the lungs, 5 in each lobe. Ten GTVs were contoured by the radiation oncologist in 10 different phases of one complete respiratory cycle. Five samples (Sample 1-5) were created using (0%, 20%, 40%, 60%, 80% i.e. taking every other phase), (0%, 30%, 60%, 90% i.e. skipping two successive phases), (0%, 20%, 30%, 50% i.e. essentially taking inhale, exhale & a phase in between), (0%, 30%, 60%), (0%, 50% i.e. using completely inhale and exhale phase only) phase GTVs, 0% is designated as the most inhaled phase and 50% as the most exhaled phase. Appropriate sample ITVs and PTVs were created in the same manner as the clinical plan which was then adapted to each sample set with minimal modification. Sample plans were compared for equivalent dose coverage, center of mass, and ITV/PTV volume differences against the clinical treatment plan. The average % ITV underestimation against the clinical ITV increased from a minimum of 7.3% in sample 1 (0%, 20%, 40%, 60%, 80%) to a maximum of 24.5% in sample 5 (0% & 50%) under the conditions of controlled breathing. A similar trend was seen in other samples with the underestimation in the ITV/PTV volume increasing with the decrease in the number of phases irrespective of the tumor location. The average variation in the center of mass of the ITV was minimal (0.43 ± 0.11 mm). Use of ITV/PTV combination derived from using less than all 10 phases resulted in the maximum clinical PTV under-dosage of 5.9% for sample 1 and 12.3% for sample 5, respectively. If fewer phases in the generation of ITV are used, a larger ITV-to-PTV margin might be necessary to get equivalent PTV coverage.

There is increased interest in the use of magnetic resonance imaging (MRI) for guiding radiation therapy (RT) in the clinical setting. In this regard, preclinical studies can play an important role in understanding the added value of MRI in RT planning. In the present study, we developed and validated a clinically relevant integrated workflow for MRI-guided volumetric arc therapy (VMAT) in a VX2 rabbit neck tumor model of HNSCC. In addition to demonstrating safety and feasibility, we examined the therapeutic impact of MR-guided VMAT using a single high dose to obtain proof-of-concept and compared the response to conventional 2D-RT. Contrast-enhanced MRI (CE-MRI) provided excellent soft tissue contrast for accurate tumor segmentation for VMAT. Notably, MRI-guided RT enabled improved tumor targeting ability and minimal dose to organs at risk (OAR) compared to 2D-RT, which resulted in notable morbidity within a few weeks of RT. Our results highlight the value of integrating MRI into the workflow for VMAT for improved delineation of tumor anatomy and optimal treatment planning. The model combined with the multimodal imaging approach can serve as a valuable platform for the conduct of preclinical RT trials.

Background Standard therapy for stage III non-small cell lung cancer with chemotherapy and conventional radiation has suboptimal outcomes. We hypothesized that a combination of surgery followed by stereotactic body radiation therapy (SBRT) would be a safe alternative. Methods Patients with stage IIIA (multistation N2) or IIIB non-small cell lung cancer were enrolled from March 2013 to December 2015. The protocol included transcervical extended mediastinal lymphadenectomy (TEMLA) followed by surgical resection, 10 Gy SBRT directed to the involved mediastinum/hilar stations and/or positive surgical margins, and adjuvant systemic therapy. Patients not suitable for anatomic lung resection were treated with 30 Gy to the primary tumor. The primary efficacy end-point was the proportion of patients with grade 3 or higher adverse events (AE) or toxicities. Results Of 10 patients, 7 patients underwent neoadjuvant chemotherapy. All patients had TEMLA. Nine of 10 patients underwent surgical resection. The remaining patient had an unresectable tumor and received 30 Gy SBRT to the primary lesion. All patients had post-operative SBRT. Median follow-up was 18 months. There were no perioperative mortalities. Six patients had any grade 3 AEs with no grade 4–5 AEs. Of these, 4 were not attributable to radiation. Pulmonary-related grade 3 AEs were experienced by 2 patients. There were no failures within the 10 Gy volume. Overall survival and progression-free survival rates at 2 years were 68% (90% CI 36–86) and 40% (90% CI 16–63), respectively. Conclusions In carefully selected patients with locally advanced non-small cell lung cancer, combining surgery with SBRT was well tolerated with no local failure. Trial registration ClinicalTrials.gov identifying number NCT01781741. Registered February 1, 2013.

Background Stereotactic Body Radiotherapy (SBRT) is an ablative dose delivery technique which requires the highest levels of precision and accuracy. Modeling dose to a lung treatment volume has remained a complex and challenging endeavor due to target motion and the low density of the surrounding media. When coupled together, these factors give rise to pulmonary induced tissue heterogeneities which can lead to inaccuracies in dose computation. This investigation aims to determine which combination of imaging techniques and computational algorithms best compensates for time dependent lung target displacements. Methods A Quasar phantom was employed to simulate respiratory motion for target ranges up to 3 cm. 4DCT imaging was used to generate Average Intensity Projection (AIP), Free Breathing (FB), and Maximum Intensity Projection (MIP) image sets. In addition, we introduce and compare a fourth dataset for dose computation based on a novel phase weighted density (PWD) technique. All plans were created using Eclipse version 13.6 treatment planning system and calculated using the Analytical Anisotropic Algorithm and Acuros XB. Dose delivery was performed using Truebeam STx linear accelerator where radiochromic film measurements were accessed using gamma analysis to compare planned versus delivered dose. Results In the most extreme case scenario, the mean CT difference between FB and MIP datasets was found to be greater than 200 HU. The near maximum dose discrepancies between AAA and AXB algorithms were determined to be marginal ( 85%) when compared to MIP and PWD (

Purpose To evaluate differences in local control (LC), disease-specific (DC), and overall survival (OS) of patients with early-stage non–small-cell lung cancer (NSCLC) treated with single- (SF) versus 5-fraction (FF) stereotactic body radiation therapy (SBRT) at 2 institutions. Patients and Methods Peripheral early-stage NSCLC cases treated with a median dose of 30 Gy in SF or a median dose of 50 Gy in FF were included per institutional practice. Kaplan-Meier and Cox models were used to assess survival. A matched-pair analysis was performed to account for imbalances. Toxicities including Common Terminology Criteria for Adverse Events (CTCAE) grade 3 pneumonitis, chest wall pain requiring long-acting narcotics, and hospitalization for respiratory events 6 months posttreatment were recorded. Results A total of 163 lesions were treated between 2007 and 2015; 65 received SF SBRT and 98 received FF SBRT. Most tumors were T1 (n = 92) and T2 (n = 34) lesions and had adenocarcinoma (n = 77) and squamous cell carcinoma (n = 46) histologies, respectively. In the matched cohort, there were no differences in OS, LC, DC, or progression-free survival between the groups. LC and OS at 1 year in the matched cohort was 95% and 88%, and 87% and 84% in the SF and FF cohorts, respectively. There was 1 grade 3 pneumonitis in the FF group, and 9 total hospitalizations post-SBRT, 3 (5%) in the SF group and 6 (6%) in the FF group. Conclusions No statistically significant differences were seen in LC or DC following SF or FF SBRT in this matched cohort of peripheral lesions. No grade 4 or higher toxicities were reported.

Purpose: Accurate knowledge about the radiationdose due to the imaging component of an OBI supported linear accelerator is very important. Though films provide excellent spatial resolution, there are problems regarding sensitivity and energy dependence at kV energies. XRQA2 film (0.1–20 cGy) is primarily for measurements in kV range. We demonstrate their use for absolute dosimetry for an OBI system. Methods: H&D curves were generated using a kV therapy x‐ray unit in the range of 0–15 cGy. A 25‐cm diameter water‐equivalent cylindrical phantom with 2.5‐cm thick slabs was used on Varian Trilogy linac. XRQA2 films were cut into circular diameter and sandwiched between 2 slabs of the cylindrical phantom to measure the percentage depth dose of the CBCT scans. Additional film pieces were wrapped around the cylinder for surface dose. To get sufficient signal, 5 CBCT scans were taken per imaging acquisition template e.g. head standard dose. After 24 hours post‐irradiation, films were scanned using Epson V700 scanner in reflection mode. Only red channel was used for dosimetric analysis using RIT software. Results: High‐Quality head acquisition template resulted in a dose at 0.2, 1.3, 2.7, and 2.7 cGy on AP, left‐lateral, posterior and right‐lateral positions of the phantom, respectively. Low‐quality thorax acquisition resulted in 1.4, 1.6, 1.5, and 1.4 cGy. The PDD at 12.5‐cm (isocenter) was of the order of 40%. While the PDD was fairly uniform from left to right, the PDD along the AP/PA direction were showing almost continuous fall off with PDD at isocenter of ∼40%. Analysis of low‐quality head PDDs show little fall off dose with depth though the overall magnitude was less with PDD at the isocenter only marginally lower than the maximum along the medial and anterior posterior axis. Conclusions: Gafchromic XRQA2 film provides a useful tool to evaluate and characterize an OBI system.

Background By avoiding chest wall resection, iridium-192 (Ir-192) high-dose-rate (HDR) intraoperative brachytherapy (IOBT) and video-assisted thoracoscopic surgery (VATS) might improve outcomes for high-risk patients requiring surgical resection for pulmonary malignancy with limited pleura and/or chest wall involvement. Methods and materials Seven patients with non-small cell lung cancer involving the pleura or chest wall underwent VATS pulmonary resections combined with HDR IOBT. After tumor extraction, an Ir-192 source was delivered via a Freiburg applicator to intrathoracic sites with potential for R1-positive surgical margins. The number of catheters, dwell position along each catheter, prescription depth, and dose were customized based on clinical needs. Results Six patients had pT3N0M0 non-small cell lung cancers. A seventh case was a recurrent sarcomatoid carcinoma. One case required conversion to open thoracotomy for pneumonectomy with en bloc chest wall resection. There were no intraoperative complications and average operative time was 5.8 hours. Five of seven patients without transmural chest wall involvement underwent rib-sparing resection. Four of the 6 patients treated with VATS and IORT remain alive in follow-up without evidence of local recurrence (median follow-up, 25 months). Noted toxicities were recurrent postoperative pneumothorax, pleural effusion with persistent chest wall pain, avid fibrosis at 2 years of follow-up, and a late traumatic rib fracture. Conclusions HDR IOBT with Ir-192 via VATS is technically feasible and safe for intrathoracic disease with pleural and/or limited chest wall involvement. Short-term morbidity associated with chest wall resection may be reduced. Additional study is required to define long-term benefits.

Purpose Radioactive seeds used in permanent prostate brachytherapy are composed of high-Z metals and may exceed 100 in a patient. If supplemental external beam treatment is administered afterward, the seeds may cause substantial dose perturbation, which is being investigated in this article. Methods and Materials Film measurements using 6-MV beam were primarily carried out using Kodak XV2 film layered above and below a nonradioactive iodine-125 ( 125 I) seed. Monte Carlo simulations were carried out using DOSXYZnrc. Other experimental comparisons looked at changing beam energy, depth, and field size, including two opposing fields’ pair. Effect of multiple seeds spatially spaced 0.5 cm vertically was also studied. Results For a single 125 I seed, on XV film, there is a localized dose enhancement of 6.3% upstream and −10.9% downstream. With two opposing fields, a cold spot around the seed of ∼3% was noticed. Increasing beam energy and field size decreased the magnitude of this effect, whereas the effect was found to increase with the increasing Z of material. DOSXYZnrc and EBT-2 film verified maximum dose enhancement of +15% upstream and −20% downstream of the 125 I seed surface. Conclusions In general, the dose perturbation because of the seeds was spatially limited to ∼2 mm upstream and ∼5 mm downstream to the incident beam. Similar to other heterogeneities, the seeds perturbation depends on incident beam energy, field size, and its Z. With multiple seeds spatially apart and multiple radiation fields routinely used in external beam radiotherapy, the cumulative effect may not result in clinically significant dose perturbation.

This study compares the EPID dosimetry algorithms of two commercial systems for pretreatment QA, and analyzes dosimetric measurements made with each system alongside the results obtained with a standard diode array. 126 IMRT fields are examined with both EPID dosimetry systems (EPIDose by Sun Nuclear Corporation, Melbourne FL, and Portal Dosimetry by Varian Medical Systems, Palo Alto CA) and the diode array, MapCHECK (also by Sun Nuclear Corporation). Twenty‐six VMAT arcs of varying modulation complexity are examined with the EPIDose and MapCHECK systems. Optimization and commissioning testing of the EPIDose physics model is detailed. Each EPID IMRT QA system is tested for sensitivity to critical TPS beam model errors. Absolute dose gamma evaluation (3%, 3 mm, 10% threshold, global normalization to the maximum measured dose) yields similar results (within 1%–2%) for all three dosimetry modalities, except in the case of off‐axis breast tangents. For these off‐axis fields, the Portal Dosimetry system does not adequately model EPID response, though a previously‐published correction algorithm improves performance. Both MapCHECK and EPIDose are found to yield good results for VMAT QA, though limitations are discussed. Both the Portal Dosimetry and EPIDose algorithms, though distinctly different, yield similar results for the majority of clinical IMRT cases, in close agreement with a standard diode array. Portal dose image prediction may overlook errors in beam modeling beyond the calculation of the actual fluence, while MapCHECK and EPIDose include verification of the dose calculation algorithm, albeit in simplified phantom conditions (and with limited data density in the case of the MapCHECK detector). Unlike the commercial Portal Dosimetry package, the EPIDose algorithm (when sufficiently optimized) allows accurate analysis of EPID response for off‐axis, asymmetric fields, and for orthogonal VMAT QA. Other forms of QA are necessary to supplement the limitations of the Portal Vision Dosimetry system. PACS numbers: 87.53.Bn, 87.53.Jw, 87.53.Kn, 87.55.Qr, 87.56.Fc, 87.57.uq

Purpose: Standard treatment plan libraries are often used to ensure a quick turn-around time for vaginal cylinder treatments. Recently there is increasing interest in transitioning from conventional 2D radiograph based brachytherapy to 3D image based brachytherapy, which has resulted in a substantial increase in treatment planning time and decrease in patient through-put. We describe a novel technique that significantly reduces the treatment planning time for CT-based vaginal cylinder brachytherapy. Material and methods: Oncentra MasterPlan TPS allows multiple sets of data points to be classified as applicator points which has been harnessed in this method. The method relies on two hard anchor points: the first dwell position in a catheter and an applicator configuration specific dwell position as the plan origin and a soft anchor point beyond the last active dwell position to define the axis of the catheter. The spatial location of various data points on the applicator’s surface and at 5 mm depth are stored in an Excel file that can easily be transferred into a patient CT data set using window operations and then used for treatment planning. The remainder of the treatment planning process remains unaffected. Results: The treatment plans generated on the Oncentra MasterPlan TPS using this novel method yielded results comparable to those generated on the Plato TPS using a standard treatment plan library in terms of treatment times, dwell weights and dwell times for a given optimization method and normalization points. Less than 2% difference was noticed between the treatment times generated between both systems. Using the above method, the entire planning process, including CT importing, catheter reconstruction, multiple data point definition, optimization and dose prescription, can be completed in ~5-10 minutes. Conclusion: The proposed method allows a smooth and efficient transition to 3D CT based vaginal cylinder brachytherapy planning. J Contemp Brachyther 2012; 4, 2: 92-100 DOI: 10.5114/jcb.2012.29365

Purpose: Traditional computed tomography (CT) units provide a maximum scan field-of-view (sFOV) diameter of 50 cm and a limited bore size, which cannot accommodate a large patient habitus or an extended simulation setup in radiation therapy (RT). Wide-bore CT scanners with increased bore size were developed to address these needs. Some scanners have the capacity to reconstruct the CT images at an extended FOV (eFOV), through data interpolation or extrapolation, using projection data acquired with a conventional sFOV. Objects that extend past the sFOV for eFOV reconstruction may generate image artifacts resulting from truncated projection data; this may distort CT numbers and structure contours in the region beyond the sFOV. The purpose of this study was to evaluate the dosimetric impact of image artifacts from eFOV reconstruction with a wide-bore CT scanner in radiotherapy (RT) treatment planning. Methods: Testing phantoms (i.e., a mini CT phantom with equivalent tissue inserts, a set of CT normal phantoms and anthropomorphic phantoms of the thorax and the pelvis) were used to evaluate eFOV artifacts. Reference baseline images of these phantoms were acquired with the phantom centrally positioned within the sFOV. For comparison, the phantoms were then shifted laterally and scanned partially outside the sFOV,more » but still within the eFOV. Treatment plans were generated for the thoracic and pelvic anthropomorphic phantoms utilizing the Eclipse treatment planning system (TPS) to study the potential effects of eFOV artifacts on dose calculations. All dose calculations of baseline and test treatment plans were carried out using the same MU. Results: Results show that both body contour and CT numbers are altered by image artifacts in eFOV reconstruction. CT number distortions of up to -356 HU for bone tissue and up to 323 HU for lung tissue were observed in the mini CT phantom. Results from the large body normal phantom, which is close to a clinical patient size, show average CT number changes of up to -49 HU. Wider distribution (i.e., standard deviation) of the HU values was seen when the phantom was placed at more than 2.8 cm beyond the 50 cm sFOV. Anthropomorphic phantom studies with several standard beam configurations show that body contour distortion causes tumor dose calculation reduction of 3.0 and 1.9% for 6 and 23 MV x-rays, respectively, when not accounting for tissue heterogeneities during dose computation. When heterogeneity correction is used in planning, the competing effects of the body contour distortion and the CT number distortion cause a smaller error in tumor dose calculation. Less than 0.9% error in calculated dose was observed in volumetric modulated arc therapy (VMAT) treatment plans. Conclusions: The image artifacts from eFOV reconstruction alter the CT numbers and body contours of the imaged objects, which has the potential to produce inaccuracies in dose calculations during radiotherapy treatment planning. The radiation therapy team should be aware of these image artifacts and their effects on target dose calculations during CT simulation as well as treatment planning.« less

Purpose To analyze the effect of tungsten shields present in a Fletcher-Suit-Delclos ovoid by comparing the dose distribution computed by a treatment planning system (TPS) to the delivered dose distribution measured by radiochromic film dosimetry. Methods and Materials Gafchromic/EBT films were carefully wrapped around the caps (diameter 20–25 mm) of shielded as well as unshielded ovoids, including their anterior and posterior ends. The ovoids were irradiated to a dose of 300 cGy using a high–dose rate remote afterloading unit. The films were scanned using Vidar VXR-16 Scanner. The dose distribution in the planes above, below, and on the sides of the ovoid were compared with the dose distribution computed by TPS, which does not account for the presence of shields. Results The dose distributions obtained about the unshielded ovoid from film dosimetry was in order of what is computed by TPS (90% measurements ± 5%, maximum 8%). The dose reduction in the anterior part of the shielded ovoid affects maximally the dose to the bladder where a reduction up to 20% was noted. The reduction of dose in the posterior part of the ovoid, which is designed to shield rectum was as high as 23%. Where the shields are not present, insignificant difference in the measured and computed dose values was noticed. Conclusions The TPS may substantially overestimate the dose to the bladder and rectum, including regions that lie in the shadow of the solid angle subtended by the shields if it does not account for the presence of tungsten shields.

Purpose: A patient-specific quality assurance (QA) method was developed to verify gantry-specific individual multileaf collimator(MLC) apertures (control points) in volumetric modulated arc therapy (VMAT) plans using an electronic portal imaging device(EPID). Methods: VMAT treatment plans were generated in an Eclipse treatment planning system (TPS). DICOM images from a Varian EPID (aS1000) acquired in continuous acquisition mode were used for pretreatment QA. Each cine image file contains the grayscale image of the MLC aperture related to its specific control point and the corresponding gantry angle information. The TPS MLC file of this RapidArc plan contains the leaf positions for all 177 control points (gantry angles). In-house software was developed that interpolates the measured images based on the gantry angle and overlays them with the MLC pattern for all control points. The 38% isointensity line was used to define the edge of the MLC leaves on the portal images. The software generates graphs and tables that provide analysis for the number of mismatched leaf positions for a chosen distance to agreement at each control point and the frequency in which each particular leaf mismatches for the entire arc. Results: Seven patients plans were analyzed using this method. The leaves with the highest mismatched rate were found to be treatment plan dependent. Conclusions: This in-house software can be used to automatically verify the MLC leaf positions for all control points of VMAT plans using cine images acquired by an EPID.

Purpose: Pulmonary nodules present unique problems during radiation treatment due to nodule position uncertainty that is caused by respiration. The radiation field has to be enlarged to account for nodule motion during treatment. The purpose of this work is to provide a method of locating a pulmonary nodule in a megavolt portal image that can be used to reduce the internal target volume (ITV) during radiation therapy. A reduction in the ITV would result in a decrease in radiation toxicity to healthy tissue. Methods: Eight patients with nonsmall cell lung cancer were used in this study. CT scans that include the pulmonary nodule were captured with a GE Healthcare LightSpeed RT 16 scanner. Megavolt portal images were acquired with a Varian Trilogy unit equipped with an AS1000 electronic portal imaging device. The nodule localization method uses grayscale morphological filtering and level-set segmentation with a prior. The treatment-time portion of the algorithm is implemented on a graphical processing unit. Results: The method was retrospectively tested on eight cases that include a total of 151 megavolt portal image frames. The method reduced the nodule position uncertainty by an average of 40% for seven out of the eight cases. The treatment phase portionmore » of the method has a subsecond execution time that makes it suitable for near-real-time nodule localization. Conclusions: A method was developed to localize a pulmonary nodule in a megavolt portal image. The method uses the characteristics of the nodule in a prior CT scan to enhance the nodule in the portal image and to identify the nodule region by level-set segmentation. In a retrospective study, the method reduced the nodule position uncertainty by an average of 40% for seven out of the eight cases studied.« less

Chemoradiation plays a core role in the definitive and preoperative management of esophageal cancer. Remarkable advances in technology now allow for the implementation of intensity modulated radiation therapy (IMRT) to minimize normal organ damage and to maximize coverage of tumorous targets. While IMRT is commonly accepted in the treatment of prostate and head and neck cancers, there have been clinical and dosimetric studies supporting the use of IMRT in esophagus cancer. In addition, the IMRT technique was recently enhanced by the availability of volumetric intensity modulated arc therapy (VMAT). VMAT may allow for faster delivery of IMRT with the advantage of normal organ protection compared to the stop-and-shoot IMRT, with faster delivery time and reduced monitor units. This review summarizes the use of chemoradiation in esophageal cancer, discusses current dosimetric data and clinical outcomes with the use of IMRT, and reviews IMRT as part of multi-modality treatment in esophageal cancer.

The GammaPlan treatment planning system does not account for the leakage and scatter dose during APS repositioning. In this study, the dose delivered to the target site and its periphery from the defocus stage and intershot couch transit (couch motion from the focus to defocus position and back) associated with APS repositioning are measured for the Gamma Knife model 4C. A stereotactic head‐frame was attached to a Leksell 16 cm diameter spherical phantom with a calibrated ion chamber at its center. Using a fiducial box, CT images of the phantom were acquired and registered in the GammaPlan treatment planning system to determine the coordinates of the target (center of the phantom). An absorbed dose of 10 Gy to the 50% isodose line was prescribed to the target site for all measurements. Plans were generated for the 8, 14 and 18 mm collimator helmets to determine the relationship of measured dose to the number of repositions of the APS system and to the helmet size. The target coordinate was identical throughout entire study and there was no movement of the APS between various shots. This allowed for measurement of intershot transit dose at the target site and its periphery. The couch was paused in the defocus position, allowing defocus dose measurements at the intracranial target and periphery. Measured dose increases with frequency of repositioning and with helmet collimator size. During couch transit, the target receives more dose than peripheral regions; however, in the defocus position, the greatest dose is superior to the target site. The automatic positioning system for the Leksell Gamma Knife model 4C results in an additional dose of up to 3.87±0.07%,4.97±0.04%, and 5.71±0.07% to the target site; its periphery receives additional dose that varies depending on its position relative to the target. There is also dose contribution to the patient in the defocus position, where the APS repositions the patient from one treatment coordinate to another. This may be important for treatment areas around critical structures within the brain. Further characterization of the defocus and transit exposures and development of a dose calculation algorithm to account for these doses would improve the accuracy of the delivered plan. PACS numbers: 87.53.‐j, 87.53.Bn, 87.53.Dq, 87.53.Ly

In intraoperative high-dose-rate (IOHDR) brachytherapy, a 2-dimensional (2D) geometry is typically used for treatment planning. The assumption of planar geometry may cause serious errors in dose delivery for target surfaces that are, in reality, curved. A study to evaluate the magnitude of these errors in clinical practice was undertaken. Cylindrical phantoms with 6 radii (range: 1.35–12.5 cm) were used to simulate curved treatment geometries. Treatment plans were developed for various planar geometries and were delivered to the cylindrical phantoms using catheters inserted into Freiburg applicators of varying dimension. Dose distributions were measured using radiographic film. In comparison to the treatment plan (for a planar geometry), the doses delivered to prescription points were higher on the concave side of the geometry, up to 15% for the phantom with the smallest radius. On the convex side of the applicator, delivered doses were up to 10% lower for small treated areas (≤ 5 catheters) but, interestingly, the dose error was negligible for large treated areas (>5 catheters). Our measurements have shown inaccuracy in dose delivery when the original planar treatment plan is delivered with a curved applicator. Dose delivery errors arising from the use of planar treatment plans with curved applicators may be significant.

In this study, we evaluate the impact of daily image-guided patient repositioning on dose delivery to prostate and sensitive organs in the treatment of prostate carcinoma with 3-dimensional conformal radiation therapy (3DCRT). Five patients with substantial ultrasound-documented interfractional prostate motion during their 3DCRT treatment course were selected. Starting with the original treatment plan, 2 additional plans were retrospectively generated for each patient. In one set, organ contours were moved for each fraction, thus simulating positioning with misalignment caused by organ motion if ultrasound guidance were not used. In a second set of plans, the isocenter was shifted, as were the organ contours, simulating realignment based on the ultrasound image. In all cases, the number of planned monitor units was set to those of the original plan. For a given patient, isodose distributions, dose-volume histograms (DVHs), equivalent uniform dose (EUD) for prostate, and generalized equivalent uniform dose (gEUDs) for bladder and rectum were calculated for each fraction and then combined for each shift condition. In all reconstructed plans, the results show no substantial changes in dose coverage of the prostate0.21% change in EUD) compared to the original plan. However, in some cases with no realignment, a larger volume of the bladder or rectum gets higher dose, with the consequent gEUD for each organ significantly greater compared to the original plan.

Purpose: Most brachytherapy planning systems are based on a dose calculation algorithm that assumes an infinite scatter environment surrounding the target volume and applicator. Dosimetric errors from this assumption are negligible. However, in intraoperative high-dose-rate brachytherapy (IOHDR) where treatment catheters are typically laid either directly on a tumor bed or within applicators that may have little or no scatter material above them, the lack of scatter from one side of the applicator can result in underdosage during treatment. This study was carried out to investigate the magnitude of this underdosage. Methods: IOHDR treatment geometries were simulated using a solid water phantom beneath an applicator with varying amounts of bolus material on the top and sides of the applicator to account for missing tissue. Treatment plans were developed for 3 different treatment surface areas (4 × 4, 7 × 7, 12 × 12 cm2), each with prescription points located at 3 distances (0.5 cm, 1.0 cm, and 1.5 cm) from the source dwell positions. Ionization measurements were made with a liquid-filled ionization chamber linear array with a dedicated electrometer and data acquisition system. Results: Measurements showed that the magnitude of the underdosage varies from about 8% to 13% of the prescription dose as the prescription depth is increased from 0.5 cm to 1.5 cm. This treatment error was found to be independent of the irradiated area and strongly dependent on the prescription distance. Furthermore, for a given prescription depth, measurements in planes parallel to an applicator at distances up to 4.0 cm from the applicator plane showed that the dose delivery error is equal in magnitude throughout the target volume. Conclusion: This study demonstrates the magnitude of underdosage in IOHDR treatments delivered in a geometry that may not result in a full scatter environment around the applicator. This implies that the target volume and, specifically, the prescription depth (tumor bed) may get a dose significantly less than prescribed. It might be clinically relevant to correct for this inaccuracy.

Background and objectives: External beam radiation (EBRT) can reduce local recurrence (LR) of soft tissue sarcomas (STS). The addition of intraoperative radiation therapy (IORT) can deliver high dose radiation boost to anticipated “high risk” margins while sparing adjacent structures. Methods: A retrospective review (2004-2012) was performed of STS treated with surgical resection and IORT using HDR brachytherapy for anticipated close/positive margins. Results: Twenty-four patients underwent 25 resections with IORT (1 patient had 2 separate recurrences). Tumors were primary in 72%, deep in 96% and intermediate/high grade in 84%. Tumor locations were extremity (44%), retroperitoneal (40%), truncal (12%) and neck (4%). Common histologies included pleomorphic (32%), liposarcoma (12%) and myxofibrosarcoma (12%). Neoadjuvantly, 3 received chemotherapy and 13 received EBRT (median 50Gy; range 45-54). Median IORT dose was 12Gy (range 10-17.5). Margins were microscopically positive in 20%; none were grossly positive. Adjuvantly, 5 received EBRT (median 46Gy, range 45-50) and 2 received chemotherapy. Median follow-up was 20.1 months (range 2.7-96.4). No recurrences occurred at the IORT sites. Two-year LR free survival was 60.8% and disease specific survival was 84%. Conclusion: Use of IORT at time of STS resection was effective at preventing LR at the treated site despite “high risk” features.

This study evaluates three‐dimensional conformal radiotherapy (3D CRT), volumetric‐ modulated arc therapy (VMAT), and dynamic conformal arc therapy (DCAT) planning techniques using dosimetric indices from Radiation Therapy Oncology Group (RTOG) protocols 0236, 0813, and 0915 for the treatment of early‐stage non‐small cell lung cancer (NSCLC) using stereotactic body radiotherapy (SBRT). Twenty‐five clinical patients, five per lung lobe, previously treated for NSCLC using 3D CRT SBRT under respective RTOG protocols were replanned with VMAT and DCAT techniques. All plans were compared using respective RTOG dosimetric indices. High‐ and low‐dose spillage improved for VMAT and DCAT plans, though only VMAT was able to improve dose to all organs at risk (OARs). DCAT was only able to provide a minimal improvement in dose to the heart and ipsilateral brachial plexus. Mean bilateral, contralateral, and V20 (percentage of bilateral lung receiving at least 20 Gy dose) doses were reduced with VMAT in comparison with respective 3D CRT clinical plans. Though some of the DCAT plans had values for the above indices slightly higher than their respective 3D CRT plans, they still were able to meet the RTOG constraints. VMAT and DCAT were able to offer improved skin dose by 1.1% and 11%, respectively. Monitor units required for treatment delivery increased with VMAT by 41%, but decreased with DCAT by 26%. VMAT and DCAT provided improved dose distributions to the PTV, but only VMAT was consistently superior in sparing dose to OARs in all the five lobes. DCAT should still remain an alternative to 3D CRT in facilities that do not have VMAT or intensity‐modulated radiotherapy (IMRT) capabilities. PACS numbers: 87.53.Ly, 87.55.dk, 87.55.D‐

We investigate the potential in using of using a graphics processor unit (GPU) for Monte-Carlo (MC)-based radiation dose calculations. The percent depth dose (PDD) of photons in a medium with known absorption and scattering coefficients is computed using a MC simulation running on both a standard CPU and a GPU. We demonstrate that the GPU′s capability for massive parallel processing provides a significant acceleration in the MC calculation, and offers a significant advantage for distributed stochastic simulations on a single computer. Harnessing this potential of GPUs will help in the early adoption of MC for routine planning in a clinical environment.

The ability of Leksell GammaPlan to perform stereotactic space localizations with image sets where there is misalignment of the patient's head (stereotactic frame and fiducial apparatus) relative to the computed tomography (CT) scanner coordinate system was studied. Misalignment is sometimes necessary for patient comfort. Results equally apply to magnetic resonance imaging. Seven 0.5 mm diameter CT-visible spheres were rigidly mounted to a string tied tightly at each end to diagonally opposite posts attached to a Leksell stereotactic frame. A standard CT fiducial box was applied to the frame in the usual clinical manner. A baseline CT scan (1 mm slice thickness) was obtained with the fiducial box perfectly aligned with the scanner axis. After localization of the image set, the (x,y,z) coordinate of the center of each sphere was recorded. Repeat CT scans with varying fiducial box misalignments with the imaging axis were subsequently obtained. The mean difference between the base line and the respective coordinates in misaligned geometries was approximately 0.2 mm (sigma=0.2 mm), well within the accuracy of the image sets and the delivery of radiosurgery with the Gamma Knife.

Purpose: Conventional treatment plans for lung radiotherapy are created using either the free breathing (FB) scheme which represents the tumor at an arbitrary breathing phase of the patient's respiratory cycle, or the average computed tomography (ACT) intensity projection over 10-binned phases. Neither method is entirely accurate because of the absence of time dependence of tumor movement. In the present “Hybrid” method, the HU of tumor in 3D space is determined by relative weighting of the HU of the tumor and lung in proportion to the time they spend at that location during the entire breathing cycle. Methods: A Quasar respiratory motion phantom was employed to simulate lung tumor movement. Utilizing 4DCT image scans, volumetric modulated arc therapy (VMAT) plans were generated for three treatment planning scenarios which included conventional FB and ACT schemes, along with a third alternative Hybrid approach. Our internal target volume (ITV) hybrid structure was created using Boolean operation in Eclipse (ver. 11) treatment planning system, where independent sub-regions created by the gross tumor volume (GTV) overlap from the 10 motion phases were each assigned a time weighted CT value. The dose-volume-histograms (DVH) for each scheme were compared and analyzed. Results: Using our hybrid technique, we have demonstrated a reduction of 1.9% – 3.4% in total monitor units with respect to conventional treatment planning strategies, along with a 6 fold improvement in high dose spillage over the FB plan. The higher density ACT and Hybrid schemes also produced a slight enhancement in target conformity and reduction in low dose spillage. Conclusion: All treatment plans created in this study exceeded RTOG protocol criteria. Our results determine the free breathing approach yields an inaccurate account of the target treatment density. A significant decrease in unnecessary lung irradiation can be achieved by implementing Hybrid HU method with ACT method second best.

Purpose: AAPM TG-76 report advises lung patients experiencing tumor motion >5mm to use some form of motion management with even smaller limit for complex/special procedures like SBRT. Generally, either respiratory gating or abdominal compression is used for motion management. In this retrospective study, we are using an innovative index, Volumetric Indices (VI) = (GTVnn AND GTV50+Xmm)/(GTVnn) to quantify how much of the tumor remains within 1, 2, and 3mm margins throughout the breathing cycle using GTV50+Xmm margin on GTV50[nn=0,10,20,…90]. Using appropriate limits, VI can provide tumor motion information and to check if RPM gates could have been used in conjunction with abdominal compression to better manage tumor motion. Methods: 64 SBRT patients with a total of 67 lung tumors were studied. 4DCT scans were taken, fully capturing tumor motion throughout the 10 phases of the breathing cycle. For each phase, Gross Tumor Volume (GTV) was segmented and appropriates structures were defined to determine VI values. For the 2mm margin, VI values less than 0.95 for peripheral lesions and 0.97 for central lesions indicate tumor movement greater than 4mm. VI values for 1mm and 3mm margins were also analyzed signifying tumor motion of 2mm & 6mm, respectively. Results: Of the 64 patients, 35 (55%) had motion greater than 4mm & could have benefited from respiratory gating. For 5/8 (63%) middle lobe lesions, 21/27 (78%) lower lobe lesions, and 10/32 (31%) upper lobe lesions, gating could have resulted in smaller ITV. 32/55 (58%) peripheral lesions and 4/12 (33%) central lesions could have had gating. Average ITV decreased by 1.25cc (11.43%) and average VI increased by 0.11. Conclusion: Out of 64 patients, 55% exhibited motion greater than 4mm even with abdominal compression. Even with abdominalcompression, lung tumors can move >4mm as the degree of pressure which a patient can tolerate, is patient specific.

Background. The GammaPlan™ treatment planning system (TPS) does not fully account for shutter dose when multiple shots are required to deliver a patient’s treatment. The unaccounted exposures to the target site and its periphery are measured in this study. The collected data are compared to a similar effect from the Gamma Knife® model 4C. Materials and methods. A stereotactic head frame was attached to a Leksell® 16 cm diameter spherical phantom; using a fiducial-box, CT images of the phantom were acquired and registered in the TPS. Measurements give the relationship of measured dose to the number of repositions with the patient positioning system (PPS) and to the collimator size. An absorbed dose of 10 Gy to the 50% isodose line was prescribed to the target site and all measurements were acquired with an ionization chamber. Results. Measured dose increases with frequency of repositioning and with collimator size. As the radiation sectors transition between the beam on and beam off states, the target receives more shutter dose than the periphery. Shutter doses of 3.53±0.04 and 1.59±0.04 cGy/reposition to the target site are observed for the 16 and 8 mm collimators, respectively. The target periphery receives additional dose that varies depending on its position relative to the target. Conclusions. The radiation sector motions for the Gamma Knife® Perfexion™ result in an additional dose due to the shutter effect. The magnitude of this exposure is comparable to that measured for the model 4C.

Purpose: Breast radiotherapy, particularly electronic compensation, may involve large dose gradients and difficult patient positioning problems. We have developed a simple self-calibrating augmented-reality system, which assists in accurately and reproducibly positioning the patient, by displaying her live image from a single camera superimposed on the correct perspective projection of her 3D CT data. Our method requires only a standard digital camera capable of live-view mode, installed in the treatment suite at an approximately-known orientation and position (rotation R; translation T). Methods: A 10-sphere calibration jig was constructed and CT imaged to provide a 3D model. The (R,T) relating the camera to the CT coordinate system were determined by acquiring a photograph of the jig and optimizing an objective function, which compares the true image points to points calculated with a given candidate R and T geometry. Using this geometric information, 3D CT patient data, viewed from the camera's perspective, is plotted using a Matlab routine. This image data is superimposed onto the real-time patient image, acquired by the camera, and displayed using standard live-view software. This enables the therapists to view both the patient's current and desired positions, and guide the patient into assuming the correct position. The method wasmore » evaluated using an in-house developed bolus-like breast phantom, mounted on a supporting platform, which could be tilted at various angles to simulate treatment-like geometries. Results: Our system allowed breast phantom alignment, with an accuracy of about 0.5 cm and 1 ± 0.5 degree. Better resolution could be possible using a camera with higher-zoom capabilities. Conclusion: We have developed an augmented-reality system, which combines a perspective projection of a CT image with a patient's real-time optical image. This system has the potential to improve patient setup accuracy during breast radiotherapy, and could possibly be used for other disease sites as well.« less

Chemoradiation plays a core role in the definitive and preoperative management of esophageal cancer. Remarkable advances in technology now allow for the implementation of intensity modulated radiation therapy (IMRT) to minimize normal organ damage and to maximize coverage of tumorous targets. While IMRT is commonly accepted in the treatment of prostate and head and neck cancers, there have been clinical and dosimetric studies supporting the use of IMRT in esophagus cancer. In addition, the IMRT technique was recently enhanced by the availability of volumetric intensity modulated arc therapy (VMAT). VMAT may allow for faster delivery of IMRT with the advantage of normal organ protection compared to the stop-and-shoot IMRT, with faster delivery time and reduced monitor units. This review summarizes the use of chemoradiation in esophageal cancer, discusses current dosimetric data and clinical outcomes with the use of IMRT, and reviews IMRT as part of multi-modality treatment in esophageal cancer.

Objective. Controversy exists regarding optimal management of high risk localized endometrial cancer. Given that vaginal brachytherapy (VB) alone is used routinely at our institution, we retrospectively reviewed our outcomes among high risk patients defined according to the PORTEC, GOG 99, and/or Aalders randomized trials of pelvic radiation versus observation to determine if acceptable rates of locoregional control could be achieved with vaginal brachytherapy alone in this highest risk patient population. Methods. The Roswell Park Cancer Institute hospital tumor registry was used to identify all patients with Stage I or IIA endometrial cancer treated between January 1992 and June 2006. A total of 464 patients were identified. Of 261 patients who received post-operative RT, 225 received VB alone. Of those 225, 87 met the high risk criteria as designated by PORTEC (at least 2 of the following high risk features: age>60, Grade 3, and/or myometrial invasion≥Occurrencesofthemathematicaloperator‘(='werechangedto‘Œ'.Pleasecheck.-->50%), GOG 99 (any age with 3 high risk features: Grade 2–3, >66% myometrial invasion, and/or LVSI; age≥50 with 2 high risk features; or age≥70 with 1 high risk feature), and/or Aalders (Stage IC, Grade 3). Descriptive recurrence statistics are provided. Results. Among 87 high risk patients treated with VB alone, 36, 77, and 14 were high risk per PORTEC, GOG 99, and Aalders respectively. Forty (46%) underwent pelvic lymph node dissection. With a median follow-up of 52 months, 3 (3.4%) pelvic recurrences were observed including 1 vaginal recurrence, 1 pelvic recurrence, and 1 local recurrence involving both the vagina and pelvis. All 3 local recurrences were successfully salvaged with pelvic RT±surgery. Conclusions. This represents one of the largest known series of high risk localized endometrial cancer treated with VB alone. The observed 3.4% locoregional recurrence compares favorably with the 5% locoregional recurrence noted among the highest risk patients receiving pelvic RT in the PORTEC, GOG 99, and Aalders randomized trials. In this single institution experience, the 3 local recurrences were salvaged. Based on these findings, we will continue to use VB alone in the adjuvant setting for patients with high risk localized endometrial cancer.

Planning intensity modulated radiation therapy (IMRT) treatment involves selection of several angle parameters as well as specification of structures and constraints employed in the optimization process. Including these parameters in the combinatorial search space vastly increases the computational burden, and therefore the parameter selection is normally performed manually by a clinician, based on clinical experience. We have investigated the use of a genetic algorithm (GA) and distributed-computing platform to optimize the gantry angle parameters and provide insight into additional structures, which may be necessary, in the dose optimization process to produce optimal IMRT treatment plans. For an IMRT prostate patient, we produced the first generation of 40 samples, each of five gantry angles, by selecting from a uniform random distribution, subject to certain adjacency and opposition constraints. Dose optimization was performed by distributing the 40-plan workload over several machines running a commercial treatment planning system. A score was assigned to each resulting plan, based on how well it satisfied clinically-relevant constraints. The second generation of 40 samples was produced by combining the highest-scoring samples using techniques of crossover and mutation. The process was repeated until the sixth generation, and the results compared with a clinical (equally-spaced) gantry angle configuration. In the sixth generation, 34 of the 40 GA samples achieved better scores than the clinical plan, with the best plan showing an improvement of 84%. Moreover, the resulting configuration of beam angles tended to cluster toward the patient's sides, indicating where the inclusion of additional structures in the dose optimization process may avoid dose hot spots. Additional parameter selection in IMRT leads to a large-scale computational problem. We have demonstrated that the GA combined with a distributed-computing platform can be applied to optimize gantry angle selection within a reasonable amount of time.

In film-based intracavitary brachytherapy for cervical cancer, position of the rectal markers may not accurately represent the anterior rectal wall. This study was aimed at analyzing the variability of rectal dose estimation as a result of interfractional variation of marker placement. A cohort of five patients treated with multiple-fraction tandem and ovoid high-dose-rate (HDR) brachytherapy was studied. The cervical os point and the orientation of the applicators were matched among all fractional plans for each patient. Rectal points obtained from all fractions were then input into each clinical treated plan. New fractional rectal doses were obtained and a new cumulative rectal dose for each patient was calculated. The maximum interfractional variation of distances between rectal dose points and the closest source positions was 1.1 cm. The corresponding maximum variability of fractional rectal dose was 65.5%. The percentage difference in cumulative rectal dose estimation for each patient was 5.4%, 19.6%, 34.6%, 23.4%, and 13.9%, respectively. In conclusion, care should be taken when using rectal markers as reference points for estimating rectal dose in HDR cervical brachytherapy. The best estimate of true rectal dose for each fraction should be determined by the most anterior point among all fractions.

Background. This study was performed to quantify the inaccuracy in clinical dose delivery due to the incomplete scatter conditions inherent in intra-operative high dose rate (IOHDR) brachytherapy. Methods. Treatment plans of 10 patients previously treated in our facility, which had irregular shapes of treated areas, were used. Treatment geometries reflecting each clinical case were simulated using a phantom assembly with no added build-up on top of the applicator. The treatment planning geometry (full scatter surrounding the applicator) was subsequently simulated for each case by adding bolus on top of the applicator. Results. For geometries representing the clinical IOHDR incomplete scatter environment, measured doses at the 5 mm and 10 mm prescription depths were lower than the corresponding prescribed doses by about 7.7% and 11.1%, respectively. Also, for the two prescription methods, an analysis of the measured dose distributions and their corresponding treatment plans showed average decreases of 1.2 mm and 2.2 mm in depth of prescription dose, respectively. Conclusions. Dosimetric calculations with the assumption of an infinite scatter environment around the applicator and target volume have shown to result in dose delivery errors that significantly decrease the prescription depth for IOHDR treatment.

Purpose: Conventional definition of respiratory gates relies on tumor motion determination in limited planes. We are proposing a new method to define the RPM gates in a consistent manner ensuring that the tumor motion is restricted to 4 mm in 3D for lung SBRT patients. The method relies on studying the ratio of volumes obtained by GTVnn intersection with GTV50+2mm margin and GTVnn where GTVnn is the GTV volume in phase nn (=0,10,30.) while GTV50+2mm is a pseudo structure created by adding an isotropic margin of 2mm to GTV50. If for any phase nn, above ratio equals 1, it ensures that the tumor motion is ≤ ±2 mm in 3D from GTV50. Methods: This method was tested for 50 patients (14-Central, 36-peripheral) to determine the RPM gates which were then compared with the gates used clinically. The minimum cut-off value of the above coefficient for its inclusion of a phase in RPM gate was taken as 0.97 for central and 0.95 for peripheral tumors. Results: 15 (30%) of the patients did not require any change in the RPM gates w.r.t. gates defined using conventional motion assessment methods. In 15(30%) cases, the RPM gates could have been smaller while in remainingmore » 20 patients, gates could have been larger. 5(/14) patient’s central tumors and 10 (/36) peripheral tumors did not need any gate change. 8(/50) patients could have RPM gate change of 30% while 10(/50) could have a gate change of up to 20%. 10, 20 & 30% RPM gate change could have happened for 11, 10 & 9 patients, respectively. Conclusion: Proposed volumetric indices based method allows a consistent, scientific and objective method to decide optimal RPM gates which is free from any inter or intra person variability and satisfies the tumor motion limits as defined by AAPM TG-76 in totality.« less

Purpose: To evaluate and verify the accuracy of alternative treatment modalities for stereotactic lung therapy with end-to-end testing. We compared three dimensional conformal therapy (3DCRT), dynamic conformal arc therapy (DCAT), intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatment using 6 MV, 6 MV flattening filter free (FFF) and 10 MV FFF photons. Methods: A QUASAR respiratory motion phantom was utilized with custom ion chamber and gafchromatic EBT2 film inserts. The phantom contained a low density lung medium with a cylindrical polystyrene tumor (35 cc). Pseudo representative structures for various organs at risk (OAR) were created. All treatment plans were created using Eclipse ver. 11 using the same image and structure sets, and delivered via Varian TrueBeam STx linear accelerator equipped with high definition MLC. Evaluation of plan quality followed ROTG 0813 criterion for conformity index (CI100%), high dose spillage, D2cm, and R50%. Results: All treatment plans met the OAR dose constraints per protocol and could be delivered without any beam hold offs or other interlocks and hence were deemed clinically safe. For equivalent beam energies, target conformity was improved for all modalities when switching to FFF mode. Treatment efficiency increased for VMAT FFF by a factor of 3–4 over IMRT, and up to factor of 7 when compared to 3DCRT. Pass rates were > 97% for all treatment using gamma criteria of 3%, 3mm. Absolute dose at iso-center was verified with ion chamber, and found to be within 2% of the treatment planning system. Conclusion: The higher dose rate associated with FFF not only reduces delivery times, but in most cases enhances plan quality. The one modality with succeeding best results for all RTOG criterions was VMAT 6 MV FFF. This end-to-end testing provides necessary confidence in the entire dose delivery chain for lung SBRT patients.

Brachytherapy plays an important role in the definitive treatment of cervical cancers by radiotherapy. In the present study, we investigated whether sliding‐window intensity‐modulated radiation therapy (IMRT) can achieve a pear‐shaped distribution with a similar sharp dose falloff identical to that of brachytherapy. The computed tomography scans of a tandem and ovoid patient were pushed to both a high dose rate (HDR) and an IMRT treatment planning system (TPS) after the rectum, bladder, and left and right femoral heads had been outlined, ensuring identical structures in both planning systems. A conventional plan (7 Gy in 5 fractions, defined as the average dose to the left and right point A) was generated for HDR treatment. The 150%, 125%, 100%, 75%, 50%, and 25% isodose curves were drawn on each slice and then transferred to the IMRT TPS. The 100% isodose envelope from the HDR plan was the target for IMRT planning. A 7‐field IMRT plan using 6‐MV X‐ray beams was generated and compared with the HDR plan using isodose conformity to the target and 125% volume, dose– volume histograms, and integral dose. The resulting isodose distribution demonstrated good agreement between the HDR and IMRT plans in the 100% and 125% isodose range. The dose falloff in the HDR plan was much steeper than that in the IMRT plan, but it also had a substantially higher maximum dose. Integral dose for the target, rectum, and bladder were found to be 6.69 J, 1.07 J, and 1.02 J in the HDR plan; the respective values for IMRT were 3.47 J, 1.79 J, and 1.34 J. Our preliminary results indicate that the HDR dose distribution can be replicated using a standard sliding‐window IMRT dose delivery technique for points lying closer to the three‐dimensional isodose envelope surrounding point A. Differences in radiobiology and patient positioning between the two techniques merit further consideration. PACS: 87.53.Jw

In this paper we determine if preoperative chemoradiation for locally advanced esophageal cancer leads to changes in cardiac ejection fraction. This is a retrospective review of 20 patients treated at our institution for esophageal cancer between 2000 and 2002. Multiple gated acquisition cardiac scans were obtained before and after platinum-based chemoradiation (50.4 Gy). Dose-volume histograms for heart, left ventricle and left anterior descending artery were analyzed. Outcomes assessed included pre- and postchemoradiation ejection fraction ratio and percentage change in ejection fraction postchemoradiation. A statistically significant difference was found between median prechemoradiation ejection fraction (59%) and postchemoradiation ejection fraction (54%) (P = 0.01), but the magnitude of the difference was not clinically significant. Median percentage volume of heart receiving more than 20, 30 and 40 Gy were 61.5%, 58.5% and 53.5%, respectively. Our data showed a clinically insignificant decline in ejection fraction following chemoradiation for esophageal cancer. We did not observe statistically or clinically significant associations between radiation dose to heart, left ventricle or left anterior descending artery and postchemoradiation ejection fraction.

Purpose: To determine whether a dose-response relationship exists between the biologic effective dose (BED) at Point A and the bladder and rectum and the clinical outcomes in our experience with external beam radiotherapy (EBRT) and high-dose-rate brachytherapy in the treatment of cervical carcinoma. Methods and Materials: This was a retrospective study. A total of 49 patients with cervical cancer were treated with a combination of EBRT (median 45 Gy, range 41.4–50.4) and high-dose-rate brachytherapy (median 18 Gy; range 18–19, in two fractions). Twenty-three patients received concomitant cisplatin-based chemotherapy. The cumulative BEDs were calculated at Point A (BED 10 ) and at bladder and rectal reference points (BED 3 ) using the linear-quadratic equation. The BED 10 values, after incorporating a time factor (BED 10 tf) in the formula, were also calculated. Results: In patients treated with RT alone, the local failure rate was 10% (1 of 10) and 19% (3 of 16) in patients receiving a BED 10 >89 Gy 10 or 10 to Point A, respectively ( p = 0.2). The corresponding local failure rates were 20% (3 of 15) and 0% (0 of 8) in patients treated with concomitant chemotherapy ( p = 0.3). In patients treated with RT alone, the local failure rate was 7.7% (1 of 13) and 23% (3 of 13) in patients with a BED 10 tf >64 Gy 10 or 10 ( p = 0.1), respectively. The median BED 3 values at the rectal and bladder point was 95.5 Gy 3 and 103.6 Gy 3, respectively. Only 1 case of Grade 2 late rectal toxicity (2%) and no late bladder toxicity occurred. Conclusion: In patients treated with RT alone, a BED 10 >89 Gy and a BED 10 tf >64 Gy indicated a trend toward a better local control rate. This difference was not observed in patients receiving chemotherapy. A BED 3 3 was associated with negligible late toxicity. Although the BED 10 in our study was about 10–15 Gy 10 less than that in the published data, the 4-year local control rate of 80% and 83% and disease-free survival rate of 75% and 70% with and without chemotherapy, respectively, compare well with the rates in other studies in the literature.

Purpose: To study breathing related tumor motion amplitudes by lung lobe location under controlled breathing conditions used in Stereotactic Body Radiation Therapy (SBRT) for NSCLC. Methods: Sixty-five NSCLC SBRT patients since 2009 were investigated. Patients were categorized based on tumor anatomic location (RUL-17, RML-7, RLL-18, LUL-14, LLL-9). A 16-slice CT scanner [GE RT16 Pro] along with Varian Realtime Position Management (RPM) software was used to acquire the 4DCT data set using 1.25 mm slice width. Images were binned in 10 phases, T00 being at maximum inspiration ' T50 at maximum expiration phase. Tumor volume was segmented in T50 using the CT-lung window and its displacement were measured from phase to phase in all three axes; superiorinferior, anterior-posterior ' medial-lateral at the centroid level of the tumor. Results: The median tumor movement in each lobe was as follows: RUL= 3.8±2.0 mm (mean ITV: 9.5 cm{sup 3}), RML= 4.7±2.8 mm (mean ITV: 9.2 cm{sup 3}), RLL=6.6±2.6 mm (mean ITV: 12.3 cm{sup 3}), LUL=3.8±2.4 mm (mean ITV: 18.5 cm{sup 3}), ' LLL=4.7±2.5 mm (mean ITV: 11.9 cm{sup 3}). The median respiratory cycle for all patients was found to be 3.81 ± 1.08 seconds [minimum 2.50 seconds, maximum 7.07 seconds]. The tumor mobility incorporatingmore » breathing cycle was RUL = 0.95±0.49 mm/s, RML = 1.35±0.62 mm/s, RLL = 1.83±0.71 mm/s, LUL = 0.98 ±0.50 mm/s, and LLL = 1.15 ±0.53 mm/s. Conclusion: Our results show that tumor displacement is location dependent. The range of motion and mobility increases as the location of the tumor nears the diaphragm. Under abdominal compression, the magnitude of tumor motion is reduced by as much as a factor of 2 in comparison to reported tumor magnitudes under conventional free breathing conditions. This study demonstrates the utility of abdominal compression in reducing the tumor motion leading to reduced ITV and planning tumor volumes (PTV)« less